AR080699A1 - Pirrolopirazinas como inhibidores de jak y syk - Google Patents
Pirrolopirazinas como inhibidores de jak y sykInfo
- Publication number
- AR080699A1 AR080699A1 ARP110100907A ARP110100907A AR080699A1 AR 080699 A1 AR080699 A1 AR 080699A1 AR P110100907 A ARP110100907 A AR P110100907A AR P110100907 A ARP110100907 A AR P110100907A AR 080699 A1 AR080699 A1 AR 080699A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- independently
- cyano
- cycloalkyl
- alkoxy
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 16
- 125000003545 alkoxy group Chemical group 0.000 abstract 8
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 7
- 125000001188 haloalkyl group Chemical group 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 3
- 125000004043 oxo group Chemical group O=* 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- -1 amino, phenyl Chemical group 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Estos compuestos inhiben JAK y SYK, resultan utiles para el tratamiento de enfermedades autoinmunologicas e inflamatorias. Reivindicacion 1: Compuesto de formula (1) en la que Y es C(R1)2(C(R1')2)m, m es 0 o 1; cada R1 es H o R1a; cada R1a es, independientemente, alquilo inferior, alcoxi inferior, fenilo, bencilo, heteroarilo, cicloalquilo, heterocicloalquilo o cicloalquil-alquilo inferior, opcionalmente sustituido con uno o más R1a', R1a' es halogeno, alquilo inferior, haloalquilo inferior, alcoxi inferior, hidroxialquilo inferior, oxo, hidroxi o ciano, cada R1' es, independientemente, H, alquilo inferior o haloalquilo inferior, R2 es, independientemente, H o R2a, R2a es, independientemente, alquilo inferior, haloalquilo inferior, alcoxi inferior, hidroxialquilo inferior, ciano, alquilo inferior, cicloalquilo o heterocicloalquilo, o R2a y R1a conjuntamente forman un anillo, opcionalmente sustituido con uno o más de entre halogeno, alquilo inferior, ciano, ciano-alquilo inferior, hidroxi, haloalquilo inferior, hidroxialquilo inferior, alcoxi inferior, alquilamino inferior o dialquilamino inferior, R3 es, independientemente, H o R3a, R3a es, independientemente, alquilo inferior, haloalquilo inferior, alcoxi inferior, hidroxialquilo inferior, ciano-alquilo inferior, C(=O)R3a' o S(=O)2R3a', cada R3a' es, independientemente, H o alquilo inferior, Q es H, halogeno, hidroxi, ciano o Q', Q' es alquilo inferior, alquenilo inferior, alquinilo inferior, cicloalquilo, fenilo, cicloalquenilo, heterocicloalquilo o heteroarilo, opcionalmente sustituidos con uno o más Qa, Qa es Qb o Qc, Qb es halogeno, oxo, hidroxi, -CN, -SCH3, -S(O)2CH3, o -S(=O)CH3, Qc es Qd o Qe; o dos Qa conjuntamente forman un sistema de anillos bicíclico, opcionalmente sustituido con uno o más Qb o Qc; Qd es -O(Qe), -S(=O)2(Qe), -C(=O)N(Qe)2, -S(O)2(Qe), -C(=O)(Qe), -C(=O)O(Qe), -N(Qe)2, N(Qe)C(=O)(Qe), -N(Qe)C(=O)O(Qe), o -N(Qe)C(=O)N(Qe)2; cada Qe es, independientemente, H o Qe', cada Qe' es, independientemente, alquilo inferior, alcoxi inferior, fenilo, bencilo, heteroarilo, cicloalquilo, heterocicloalquilo o cicloalquil-alquilo inferior, opcionalmente sustituido con uno o más Qf, Qf es Qg o Qh, Qg es halogeno, hidroxi, ciano, oxo, o C(=O)(Qh), Qh es alquilo inferior, haloalquilo inferior, alcoxi inferior, amino, fenilo, bencilo, cicloalquilo, heterocicloalquilo o heteroarilo, opcionalmente sustituidos con uno o más Qi, y Qi es halogeno, hidroxi, ciano, alquilo inferior, haloalquilo inferior o alcoxi inferior, o una sal farmacéuticamente aceptable de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31599910P | 2010-03-22 | 2010-03-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080699A1 true AR080699A1 (es) | 2012-05-02 |
Family
ID=43983677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100907A AR080699A1 (es) | 2010-03-22 | 2011-03-21 | Pirrolopirazinas como inhibidores de jak y syk |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8481541B2 (es) |
| EP (1) | EP2550274A1 (es) |
| JP (1) | JP5667692B2 (es) |
| KR (1) | KR20130004342A (es) |
| CN (1) | CN102812029A (es) |
| AR (1) | AR080699A1 (es) |
| BR (1) | BR112012023752A2 (es) |
| CA (1) | CA2786402A1 (es) |
| MX (1) | MX2012010610A (es) |
| RU (1) | RU2012142550A (es) |
| TW (1) | TW201136936A (es) |
| WO (1) | WO2011117160A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2571881A1 (en) * | 2010-05-20 | 2013-03-27 | F.Hoffmann-La Roche Ag | Pyrrolopyrazine derivatives as syk and jak inhibitors |
| RU2012152352A (ru) * | 2010-05-20 | 2014-06-27 | Ф. Хоффманн-Ля Рош Аг | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-b]ПИРАЗИН-7-КАРБОКСАМИДА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ JAK И SYK |
| CA2844730A1 (en) | 2011-09-01 | 2013-03-07 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
| JP6173327B2 (ja) | 2011-11-01 | 2017-08-02 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | イミダゾピリダジン化合物 |
| AR089682A1 (es) | 2012-01-10 | 2014-09-10 | Hoffmann La Roche | Compuestos de piridazina-amida |
| US20170100396A1 (en) | 2015-10-07 | 2017-04-13 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine derivatives for use in the treatment, amelioration or prevention of influenza |
| EA201891620A1 (ru) | 2016-02-05 | 2019-02-28 | Денали Терапьютикс Инк. | Ингибиторы взаимодействующей с рецептором протеинкиназы 1 |
| PL3552017T3 (pl) | 2016-12-09 | 2022-08-08 | Denali Therapeutics Inc. | Związki użyteczne jako inhibitory RIPK1 |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| BR112022011838A2 (pt) | 2019-12-20 | 2022-08-30 | Pfizer | Derivados de benzimidazol |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN115697492B (zh) * | 2021-03-09 | 2025-07-22 | 石药集团中奇制药技术（石家庄）有限公司 | 一种含有三环杂芳基的化合物的用途 |
| MX2024008648A (es) | 2022-01-12 | 2024-09-23 | Denali Therapeutics Inc | Formas cristalinas de (s)-5-bencil-n-(5-metil-4-oxo-2,3,4,5-tetrah idropirido [3,2- b][1,4]oxacepin-3-il)-4h-1,2,4-triazol-3-carboxam ida. |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL150388A0 (en) | 1999-12-24 | 2002-12-01 | Aventis Pharma Ltd | Azaindoles |
| GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| AU2003214412A1 (en) | 2002-03-28 | 2003-10-13 | Eisai R & D Management Co., Ltd. | 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders |
| DK1696920T3 (en) | 2003-12-19 | 2015-01-19 | Plexxikon Inc | RELATIONS AND PROCEDURES FOR THE DEVELOPMENT OF LAW MODULATORS |
| US7456289B2 (en) | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
| EP2251341A1 (en) | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
| NZ601687A (en) | 2006-01-17 | 2014-03-28 | Vertex Pharma | Azaindoles useful as inhibitors of janus kinases |
| CL2007002617A1 (es) * | 2006-09-11 | 2008-05-16 | Sanofi Aventis | Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto. |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
| JP5287253B2 (ja) | 2007-01-12 | 2013-09-11 | アステラス製薬株式会社 | 縮合ピリジン化合物 |
| ES2373253T3 (es) | 2007-05-25 | 2012-02-01 | Elan Pharmaceuticals Inc. | Pirazolopirrolidinos como inhibidores de gamma secretasa. |
| WO2009055696A1 (en) * | 2007-10-25 | 2009-04-30 | Achaogen, Inc. | CARBACEPHEM β-LACTAM ANTIBIOTICS |
| CN101939324B (zh) | 2008-02-25 | 2014-10-15 | 霍夫曼-拉罗奇有限公司 | 吡咯并吡嗪激酶抑制剂 |
| CN101952295B (zh) | 2008-02-25 | 2013-11-20 | 霍夫曼-拉罗奇有限公司 | 吡咯并吡嗪激酶抑制剂 |
| CN101945877B (zh) | 2008-02-25 | 2013-07-03 | 霍夫曼-拉罗奇有限公司 | 吡咯并吡嗪激酶抑制剂 |
| PT2250172E (pt) | 2008-02-25 | 2011-11-30 | Hoffmann La Roche | Inibidores de pirrolpirazina-cinase |
| ATE519763T1 (de) | 2008-02-25 | 2011-08-15 | Hoffmann La Roche | Pyrrolopyrazin-kinasehemmer |
| US8518945B2 (en) * | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
-
2011
- 2011-03-03 US US13/039,433 patent/US8481541B2/en not_active Expired - Fee Related
- 2011-03-21 CN CN2011800148817A patent/CN102812029A/zh active Pending
- 2011-03-21 EP EP11711062A patent/EP2550274A1/en not_active Withdrawn
- 2011-03-21 TW TW100109582A patent/TW201136936A/zh unknown
- 2011-03-21 AR ARP110100907A patent/AR080699A1/es unknown
- 2011-03-21 JP JP2013500446A patent/JP5667692B2/ja not_active Expired - Fee Related
- 2011-03-21 WO PCT/EP2011/054171 patent/WO2011117160A1/en not_active Ceased
- 2011-03-21 CA CA2786402A patent/CA2786402A1/en not_active Abandoned
- 2011-03-21 RU RU2012142550/04A patent/RU2012142550A/ru not_active Application Discontinuation
- 2011-03-21 MX MX2012010610A patent/MX2012010610A/es active IP Right Grant
- 2011-03-21 BR BR112012023752A patent/BR112012023752A2/pt not_active IP Right Cessation
- 2011-03-21 KR KR1020127027328A patent/KR20130004342A/ko not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012023752A2 (pt) | 2019-09-24 |
| EP2550274A1 (en) | 2013-01-30 |
| JP2013522337A (ja) | 2013-06-13 |
| KR20130004342A (ko) | 2013-01-09 |
| TW201136936A (en) | 2011-11-01 |
| US20110230414A1 (en) | 2011-09-22 |
| US8481541B2 (en) | 2013-07-09 |
| MX2012010610A (es) | 2012-10-03 |
| CN102812029A (zh) | 2012-12-05 |
| WO2011117160A1 (en) | 2011-09-29 |
| JP5667692B2 (ja) | 2015-02-12 |
| RU2012142550A (ru) | 2014-04-27 |
| CA2786402A1 (en) | 2011-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR080699A1 (es) | Pirrolopirazinas como inhibidores de jak y syk | |
| AR074459A1 (es) | Pirrolopirazinil-ureas utiles para el tratamiento de enfermedades autoinmunes e inflamatorias. | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| AR098912A1 (es) | Inhibidores de syk | |
| PE20141540A1 (es) | Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2 | |
| PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
| AR087288A1 (es) | Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como moduladores de receptores de c5a | |
| AR070468A1 (es) | Pirrolopirazinas inhibidores de quinasa | |
| AR079690A1 (es) | Derivados heterociclicos de pirrol[2,3-b]piridina, composiciones farmaceuticas que los contienen, procedimiento para prepararlos y uso de los mismos como agentes anticancer. | |
| PE20142164A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| PE20142148A1 (es) | Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio | |
| PE20151601A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| PE20091099A1 (es) | Derivados de aminobenzamida como agentes utiles para controlar parasitos animales | |
| PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| CO6251357A2 (es) | Nuevos derivados de acido azabifenilaminobenzoico | |
| PE20151752A1 (es) | Amidas heterociclicas como inhibidores de cinasas | |
| PE20150399A1 (es) | Nuevos derivados de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR070395A1 (es) | Derivados de 4,5-dihidro-oxazol-2-il- amina | |
| AR091285A1 (es) | Inhibidores de bromodominio y sus usos | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| PE20090054A1 (es) | Derivados de purina | |
| PE20170327A1 (es) | 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4d] [1,3] TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS | |
| AR067058A1 (es) | Oxazolidinonas sustituidas y su uso para preparar medicamentos | |
| PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |